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ﬁbrosis: transport in cystic ﬁbrosis cells, and
additivity to channel-targeting drugs†
Hongyu Li, a Hennie Valkenier, ‡b Abigail G. Thorne,b Christopher M. Dias, b
James A. Cooper, b Marion Kieﬀer, b Nathalie Busschaert, §c
Philip A. Gale, {*c David N. Sheppard *a and Anthony P. Davis *b
Defective anion transport is a hallmark of the genetic disease cystic ﬁbrosis (CF). One approach to restore
anion transport to CF cells utilises alternative pathways for transmembrane anion transport, including
artiﬁcial anion carriers (anionophores). Here, we screened 22 anionophores for biological activity using
ﬂuorescence emission from the halide-sensitive yellow ﬂuorescent protein. Three compounds possessed
anion transport activity similar to or greater than that of a bis-(p-nitrophenyl)ureidodecalin previously
shown to have promising biological activity. Anion transport by these anionophores was concentration-
dependent and persistent. All four anionophores mediated anion transport in CF cells, and their activity
was additive to rescue of the predominant disease-causing variant F508del-CFTR using the clinically-
licensed drugs lumacaftor and ivacaftor. Toxicity was variable but minimal at the lower end. The results
provide further evidence that anionophores, by themselves or together with other treatments that
restore anion transport, oﬀer a potential therapeutic strategy for CF.Introduction
Biologically-active synthetic transmembrane anion transporters
(anionophores) have therapeutic potential in the genetic
disease cystic brosis (CF).1–5 CF is caused by dysfunction of the
anion channel cystic brosis transmembrane conductance
regulator (CFTR), which plays a pivotal role in salt and water
transport across epithelia.6–8 Although some drugs have been
developed and clinically-licensed that target defects in CFTR,
the large number of disease-causing variants and their rarity
potentially limits the use of these agents.9–12 By contrast, anio-
nophores might be developed to provide therapeutics for alld Neuroscience, University of Bristol,
alk, Bristol BS8 1TD, UK. E-mail: D.N.
, Cantock's Close, Bristol BS8 1TS, UK.
thampton SO17 1BJ, UK. E-mail: philip.
ESI) available: Experimental details and
binding studies, transport studies and
42c
ular NanoSystems, Universite´ libre de
0 Brussels, Belgium.
try, Tulane University, New Orleans, LA
ney, School of Chemistry (F11), NSW
hemistry 2019individuals living with CF.13 They might be used alone or as part
of a combination therapy with drugs that target faulty CFTR.
We have developed a range of anionophores based on
powerful anion binding sites created from hydrogen bond
donor groups mounted on alicyclic scaﬀolds, which function as
mobile anion carriers (Fig. 1).14–16 Scaﬀolds include
steroids,15,17,18 trans-decalins,19,20 and substituted cyclohex-
anes,21 with the common design motif being the positioning of
axially-directed H bond donors in 1,5 relationships. Confor-
mational factors promote the convergence of NH groups to
create binding sites with high aﬃnities for inorganic
anions.14,18,21 We have also developed alternatives, including
squaramides,22 hexa-substituted benzenes,23 anthracenes24 and
compounds based on the tris(2-aminoethyl)amine (tren) scaf-
fold.16,25 While most studies of anionophores have used
synthetic vesicles, we recently showed that some are also active
in cells. An assay employing the genetically-encoded halide-
sensitive uorophore yellow uorescent protein (YFP)26–28 gave
encouraging results with several anionophores. In particular,
the decalin-based bis-(p-nitrophenyl)-ureidodecalin 11 (Fig. 1)
showed especially promising activity, including potency,
persistence and a lack of toxic eﬀects.29
The identication of optimal anionophores for CF treatment
will require the screening of numerous candidates. The assay
employed to identify 11 requires time-consuming uorescence
microscopy and is unsuitable for this purpose. Here, we report
the implementation of a YFP-based assay using a standard plate
reader. The assay was applied to a panel of 22 test compoundsChem. Sci., 2019, 10, 9663–9672 | 9663
Fig. 1 Structures of compounds 1–22 studied in this work.
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View Article Onlinebelonging to several compound classes, and was also used to
extend the range of cell types studied. We identify three agents
which show similar or improved performance relative to 11,
including one which is nearly twice as active. We nd that these
agents are potent and persistent, and provide further evidence
that anionophore activity is possible without cytotoxicity. We
also nd that the anionophores are eﬀective in CF cells, and
demonstrate that their activity is additive to rescue of the
predominant disease-causing variant, F508del-CFTR, using the
clinically-licensed drugs lumacaor and ivacaor. Taken
together, the data suggest that anionophores, either alone or
together with CFTR modulators, are a potential therapeutic
strategy for CF with wide utility.
Results
Anionophore synthesis and studies in synthetic membranes
Fig. 1 shows the anionophores investigated in this study,
grouped according to structural similarity. We reported previ-
ously compounds 1–8, 11, 14–22 (for references, see Table 1).
The new compounds 9, 10 and 12, 13 were prepared according
to known methodology as discussed in the ESI.†9664 | Chem. Sci., 2019, 10, 9663–9672The four new anionophores were tested for aﬃnity to Cl (in
CHCl3 and DMSO, with tetra-alkylammonium counter-ions), and
for anion transport (Cl/NO3
 exchange) when preloaded into
200 nm large unilamellar vesicles (LUVs). The latter assay was
performed using the well-established “lucigenin method”30 in
which Cl inux into vesicles is followed through quenching of
uorescence from the halide-sensitive uorophore lucigenin. The
results are listed in Table 1, accompanied by corresponding
values for the previously-reported compounds where available.
Transport activities are given either as specic initial rates [I],
a quantity dened in previous work to allow comparison of
anionophores with widely diﬀering activities,20 or as EC50, 270 s
values (see Table 1 footnote h).16 Table 1 also lists parameters
which are relevant to pharmaceutical potential (molecular weight
and clog P) together with the results of a “deliverability” test
applied to transporters 5–16 and 19–22. In this test, anion
transport by anionophores delivered externally to LUVs is
compared with their action when preloaded into LUV
membranes.24,29,32 Interestingly, Table 1 reveals that the new
compound 12 has closely comparable properties to 11, the decalin
previously found to show promising biological activity,29 while
promoting a considerably higher rate of transport in vesicles.This journal is © The Royal Society of Chemistry 2019
Table 1 Anionophore properties and binding/transport data
Compound Binding Transport in LUVs Transport in YFP-FRT cellsb
Reference
MW
(g mol1) clog Pc
Ka to Cl
 in
CHCl3
d (M1)
Ka to Cl
 in
DMSOe (M1)
Specic initial
rate [I]f (s1)
Delivera-
bilityg
EC50, 270 s (mol%)
and nh
Corrected absolute initial
slope |dF/dT| (103)i (s1)
1 264 2.6 2.6  102 1.38 (1.7) 0 22
2 400 4.6 4.6  102 0.06 (1.2) 0.3 22
3 536 6.6 6.4  102 75b 0.01 (1.1) 0 22
4 790 7.2 n.d.j 3.8  102 5 0.2 23
5 859 10.9 1.5  107 3.0  102 56 0.24b 0 23
6 1063 13.9 6.8  108 4.5  102 350 0.11b 0.2 23
7 1015 13.5 n.d.j 3.9  102 50 0.18b 0.2 23
8 1021 13.9 n.d.j 3.9  102 140 0.30b 0 21
9a 689 6.6 1.4  108 n.d. 9 1.55 1.1
10a 825 8.6 2.5  108 n.d. 19 0.95 0.7
11 569 4.5 n.d.j 6.8  102 22 1.36 12.6 29
12a 601 4.8 n.d.j 1.7  103 310 1.12 17.2
13a 685 7.2 1.5  109 n.d. 370 0.24 3.3
14 647 7.3 1.2  108 1.5  103 200 2.02b 1.1 20
15 783 9.3 4.7  108 2.4  103 2600 0.41b 22.6 20
16 867 11.6 5.0  108 2.6  103 3800 0.03 0 20
17 552 4.2 5.2  105b 1.8  103 0.31 (1.9) 0.5 16 and 25
18 756 7.3 1.5  107b 9.6  102 36b 0.077 (4.8) 1.1 16 and 25
19 960 10.4 1.5  109b 4.4  103 590b 2.98b 0.042 (5.0) 12.2 16 and 25
20 537 6.9 n.d.j 2.6  103 2100 0.82 8.4 24
21 583 9.3 n.d.j 2.2  103 1200 0.62 1.7 24
22 719 11.4 n.d.j 3.0  103 1900 0.45 9.0 24
a New compound. b New data. c Calculated using TorchV10lite. d Obtained by extraction of Et4N
+Cl from water into chloroform at 303 K.31
e Obtained from 1H NMR titrations with Bu4N
+Cl in DMSO-d6/H2O (200 : 1) at 298 K.
f Transporter preincorporated in LUVs. Specic initial
rate [I] ¼ initial slope of F0/F vs. time t, divided by the transporter/lipid ratio in LUVs. LUVs (200 nm) are composed of 70% POPC + 30%
cholesterol + transporter. Anion transport is induced by a [NaCl] gradient of 25 mM, with 225 mM NaNO3 inside and outside LUVs.
g Deliverability index (D) calculated by dividing I for the external addition of anionophore by that for preincorporated anionophore. Highly
deliverable agents show values greater than 1, for reasons discussed in ref. 32. h Concentration of externally added transporter (mol% carrier to
lipid) for 50% Cl eﬄux in 270 s and Hill coeﬃcient (n) during Cl/NO3
 experiments, using LUVs (POPC; 200 nm) with 490 mM NaCl inside
and 490 mM NaNO3 outside.
i Measurements from cells exposed to DMSO only was subtracted from that of DMSO (0.5% v/v) + transporter (50
mM) mixtures. j Not determined due to low solubility in chloroform.
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View Article OnlineEvaluation of anionophore activity in cells using
a uorescence-based assay
We recently demonstrated that anion transport by aniono-
phores in individual cells can be monitored in real time using
the genetically-encoded halide sensitive uorophore YFP-
H148Q/I152L.26–29 To eﬃciently identify compounds with
improved biological activity, we have adapted our assay to
investigate anionophore-mediated anion transport in a pop-
ulation of cells using Fischer rat thyroid (FRT) cells expressing
YFP-H148Q/I152L (YFP-FRT cells) and a microplate reader.27 We
treated YFP-FRT cells with anionophores (nal concentration,
1–50 mM) or the vehicle DMSO (0.1–0.5% v/v) by direct addition
to the phosphate-buﬀered saline (PBS) bathing the cells. Aer
incubating YFP-FRT cells with anionophores for 10 minutes at
37 C, we evaluated anion transport activity by adding I (100
mM), using a PBS iodide solution with Cl replaced by I, and
following cell uorescence for 14 s. FRT cells are relatively
impermeable to anions because they lack key ion channels
found in epithelial cells, including CFTR.33 Thus, in the absence
of anionophore, iodide cannot enter YFP-FRT cells and no
quenching of uorescence occurs. By contrast, in the presenceThis journal is © The Royal Society of Chemistry 2019of an anionophore, iodide inux occurs leading to uorescence
quenching.29
Fig. 2a shows representative time courses for YFP-FRT cells
treated with 22 test anionophores (50 mM) and the vehicle
DMSO (0.5% v/v). When YFP-FRT cells were treated with DMSO,
or if neither anionophore nor I were added, there was little or
no change in the time course of uorescence (Fig. 2a and ref.
29). Fig. 2a demonstrates that the previously-studied 11 gener-
ated a pronounced decay of uorescence, recapitulating results
using uorescence microscopy.29 Interestingly, several other
anionophores, including 12, 15 and 19 caused notable decays in
uorescence (Fig. 2a).
To quantify anion transport by diﬀerent anionophores, we
tted rst order exponential functions to the iodide-induced
uorescence decay to measure the initial slope, averaging
values over multiple experiments. Fig. 2b and Table 1 summa-
rise the data. Consistent with our previous results,29 we
observed a wide range of anion transport activity. Some anio-
nophores demonstrated little or no anion transport in YFP-FRT
cells (e.g. 1–3), others exhibited intermediate levels (e.g. 13, 20
and 22), whereas 19, 12, and particularly 15 possessed levels ofChem. Sci., 2019, 10, 9663–9672 | 9665
Fig. 2 Screening anionophores for biological activity. (a) Representative time courses of cell ﬂuorescence in YFP-FRT cells treated with the
indicated anionophores (50 mM) or the vehicle DMSO (0.5% v/v) normalized to the ﬂuorescence intensity before I (100mM) addition at t¼ 0 s. (b)
Anionophore-mediated anion transport in YFP-FRT cells determined from the initial slope of the ﬂuorescence decay. The vertical dashed line
indicates the initial slope of the ﬂuorescence decay for control cells treated with DMSO (0.5% v/v). Data are means  SEM (n ¼ 16–64 from at
least four independent experiments); **, P < 0.01 vs. DMSO.
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View Article Onlineactivity similar to or greater than that of 11 (Fig. 2b). We
therefore selected for further study 11, 12, 15 and 19.Anion transport by anionophores in CF cells
To develop anionophores as a potential therapy for CF, it is
necessary to demonstrate eﬃcacy in epithelial tissues aﬀected
by the disease, particularly the respiratory airways, the major
site of disease in CF.7 To begin to test anionophores in CF
airway epithelial cells, we utilised the CF bronchial epithelial
cell line CFBE41o engineered to express YFP-H148Q/I152L
(YFP-CFBE cells).34,35 One advantage of using YFP-CFBE cells is
that they endogenously express the Ca2+-activated Cl channel
(CaCC), unlike YFP-FRT cells.33 Thus, using YFP-CFBE cells, we
directly compared anion transport by anionophores with that of
the CaCC, an alternative pathway to restore anion transport in
CF.13
Fig. 3a demonstrates that 11, 12, 15 and 19 mediated anion
transport in YFP-CFBE cells. For each anionophore, raising the
transporter concentration increased the rate of uorescence
decay and hence, anion transport activity. ESI Fig. S16† shows
that 11 and 12 exhibited identical concentration–response
relationships in YFP-CFBE and YFP-FRT cells, that of 19 was
similar in both cell types, but 15 was less eﬃcacious in YFP-9666 | Chem. Sci., 2019, 10, 9663–9672CFBE cells. These variations in behaviour may result from the
diﬀerent physical properties of the anionophores. For example,
the poorly deliverable 15 may not be able to penetrate the YFP-
CFBE cells, given their barrier function in the respiratory
airways.
Anion transport by CaCC in YFP-CFBE cells was stimulated
using the P2Y (purinergic G protein-coupled) receptor agonist
UTP (for chemical structure, see ESI Fig. S15†), which activates
the channel by elevating the intracellular Ca2+ concentration
(Fig. 3).13 Comparison of anion transport by anionophores and
CaCCs (Fig. 3) reveals two important points. First, low concen-
trations of anionophores elicited anion transport equivalent to
that achieved by CaCC activation. Fig. 3a demonstrates that the
anionophore concentrations matching the eﬀect of UTP (1 mM)
were 19 (1 mM)¼ 15 (1 mM)¼ 12 (1 mM)$ 11 (5 mM). Second, for
the trans-decalin anionophores 11, 12 and 15 CaCC activation
was either without eﬀect or weakly additive to anionophore-
mediated anion transport (Fig. 3b). By contrast, for the tren-
based compound 19, CaCC activation was strongly additive to
anionophore-mediated anion transport (Fig. 3b). As a control,
we tested the eﬀect of the CaCC inhibitor CaCCinh-A01 36 (for
chemical structure, see ESI Fig. S15†). Addition of CaCCinh-A01
nullied the eﬀect of UTP in the case of the trans-decalins 11, 12
and 15 (ESI Fig. S17†). In the case of 19, CaCCinh-A01 alsoThis journal is © The Royal Society of Chemistry 2019
Fig. 3 Anion transport by anionophores and CaCC activation in CF cells. (a) Relationship between anionophore concentration and anion
transport activity in YFP-CFBE cells for 11, 12, 15 and 19. Crosses and dashed lines indicate the amount of anion transport mediated by CaCC
activation with UTP (1 mM). For representative time courses of cell ﬂuorescence from YFP-CFBE cells treated with test anionophores, see ESI
Fig. S16.† (b) Anion transport by YFP-CFBE cells treated with anionophores (50 mM) and UTP (1 mM) individually or together. Data are means 
SEM (n ¼ 12–64 from at least four independent experiments); in (a), dotted lines are the ﬁt of ﬁrst-order functions to mean data.
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View Article Onlineshowed evidence of anionophore inhibition (ESI Fig. S17†). This
eﬀect is unlikely to reect a specic interaction, and may
suggest that 19 is vulnerable to inhibition by aromatic carbox-
ylic acids. Taken together, the data suggest that anion transport
by anionophores in YFP-CFBE cells is independent of CaCC
activation and for 19 it is additive to that of CaCC.Anion transport by anionophores is additive to that of CFTR
Next, we sought to learn whether the activities of 11, 12, 15, and
19 are additive to that of CFTR. For these studies, we used FRT
cells co-expressing wild-type human CFTR and YFP-H148Q/
I152L (WT-CFTR-YFP-FRT cells).28 ESI Fig. S19A† shows repre-
sentative time courses of uorescence decay for the aniono-
phores 11, 12, 15, and 19 (all tested at 50 mM) in the absence and
presence of the cAMP agonist forskolin (10 mM) and the CFTR
inhibitor CFTRinh-172 (10 mM),37 while ESI Fig. S19B† summa-
rises data frommultiple experiments (for chemical structures of
CFTR modulators, see ESI Fig. S18†). Forskolin robustly stim-
ulated anion transport in WT-CFTR-YFP-FRT cells and the
response was inhibited, albeit incompletely by CFTRinh-172 (ESI
Fig. S19†). ESI Fig. S19† demonstrates that anion transport by
each of the anionophores was additive to that of forskolin.
CFTRinh-172 was without eﬀect on anion transport by 11 and 12,
but inhibited the activity of 19 (P < 0.001) and caused a small,
albeit signicant, increase in anion transport by 15 (P < 0.001)
(ESI Fig. S19†). This latter eﬀect is diﬃcult to explain andmerits
further investigation.This journal is © The Royal Society of Chemistry 2019To learn whether anionophores are additive to small mole-
cules that rescue disease-causing CFTR variants, we used FRT
cells co-expressing F508del-CFTR, the predominant CF muta-
tion and YFP-H148Q/I152L (F508del-CFTR-YFP-FRT cells).28 To
rescue the plasma membrane expression of F508del-CFTR, we
used low temperature or the clinically-licensed CFTR corrector
lumacaor,38,39 while to increase its activity, we used the
clinically-licensed CFTR potentiator ivacaor.40
Fig. 4 shows summary anion transport data for control
F508del-CFTR-YFP-FRT cells grown at 37 C and cells incubated
at 27 C for 24 h or pre-treated with lumacaor (3 mM) at 37 C
for 24 h to rescue the plasma membrane expression of F508del-
CFTR. Representative time courses of uorescence decay are
shown in ESI Fig. S20.† The anionophores 11, 12, 15, and 19 all
mediated anion transport in control F508del-CFTR-YFP-FRT
cells grown at 37 C, whereas forskolin (10 mM) had little
eﬀect (Fig. 4a). Low temperature incubation or treatment with
lumacaor enhanced forskolin-mediated Cl transport by
F508del-CFTR, but had little or no eﬀect on anionophore-
mediated anion transport (Fig. 4a).
Fig. 4 demonstrates that following rescue of its plasma
membrane expression, ivacaor (1 mM) increased the amount of
anion transport achieved by F508del-CFTR expressing FRT cells
compared to the action of forskolin (10 mM). When added
together with forskolin and ivacaor, the anionophores 11, 12,
15, and 19 increased further the amount of anion transport
generated by F508del-CFTR-YFP-FRT cells (Fig. 4b). Compar-
ison of the magnitude of anion transport in the absence andChem. Sci., 2019, 10, 9663–9672 | 9667
Fig. 4 Anion transport by anionophores and CFTRmodulators in FRT cells expressing F508del-CFTR. (a) Magnitude of anion transport generated
by test anionophores (50 mM) compared to that achieved by stimulating F508del-CFTR with forskolin (Fsk; 10 mM) for the indicated treatments of
F508del-CFTR-YFP-FRT cells. (b) Magnitude of anion transport generated by test anionophores (50 mM) together with F508del-CFTR stimulation
with forskolin (10 mM) and potentiation with ivacaftor (1 mM) compared to the action of forskolin and ivacaftor on F508del-CFTR for the indicated
treatments of F508del-CFTR-YFP-FRT cells. For representative time courses of cell ﬂuorescence, see ESI Fig. S20.† Fluorescence quenching by
the anionophore vehicle (DMSO, 0.5% v/v) was subtracted from each test measurement. Data are means  SEM (n ¼ 20–52 from at least four
independent experiments); **, P < 0.01 vs. forskolin; ##, P < 0.01 vs. anionophore; ++, P < 0.01 vs. forskolin + ivacaftor.
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View Article Onlinepresence of anionophores demonstrates that their eﬀects were
additive to those of forskolin and ivacaor (Fig. 4b). Of note,
similar results were recently reported using F508del-CFTR-YFP-
FRT cells treated with lumacaor, ivacaor and anionophores
derived from prodigiosin and tambjamine.41 Thus, aniono-
phores mediate anion transport in cells expressing wild-type
and F508del-CFTR and their eﬀects are additive to the action
of drugs that rescue F508del-CFTR.Anionophore delivery, persistence and eﬃcacy
In previous work,29 we demonstrated that the anionophore 11
remains active at the plasma membrane for >2 h. To investigate
further the relationship between anionophore delivery to cell
membranes, the longevity of their action and their eﬃcacy, we
undertook two types of experiment. First, using the microplate
reader, we tested the eﬀects of diﬀerent incubation periods on
anion transport by 11, 12, and 19 (each tested at 1, 10 and 50
mM). Second, using uorescence microscopy, we examined the
persistence of anion transport by the two most promising
anionophores, 11 and 12, (both tested at 10 mM) aer diﬀerent
incubation periods. Because of its reduced deliverability, we did
not use 15 in these experiments. Several conclusions can be9668 | Chem. Sci., 2019, 10, 9663–9672drawn from the data in ESI Fig. S21 and S22.† First, anion
transport by anionophores is concentration-dependent. Second,
increasing the incubation period improves anion transport by
some, but not all anionophores. Third, for at least two anio-
nophores, 11 and 12, their eﬀects show noticeable persistence.Cytotoxicity of anionophores in CF cells
We previously evaluated the cytotoxicity of 11 and a related
decalin bis-urea in three diﬀerent epithelial cell lines (MDCK,
FRT and HeLa), using the reagent XTT to measure mitochon-
drial activity.29 Employing the same method, we assessed the
cytotoxicity of 11, 12, 15, and 19 in YFP-CFBE cells. We also
examined overall toxicity and the induction of apoptosis in YFP-
FRT cells, using the IncuCyte ZOOM™ (Essen Bioscience) live-
cell analysis system. The anionophores 15, 12, and 19 showed
some signs of cytotoxicity in YFP-CFBE cells at the highest
concentrations tested with 19 (50 mM) giving the strongest eﬀect
(ESI Fig. S23†). The IncuCyte ZOOM™ measurements revealed
some toxicity for all four compounds at 50 mM, but the eﬀects
were strongly delayed for 11 (ESI Fig. S24†). At 10 mM, 11 showed
no toxicity while 12, 15 and 19 caused some cell death. Notably,
the apoptosis assay gave negative results for 11 at allThis journal is © The Royal Society of Chemistry 2019
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View Article Onlineconcentrations tested (ESI Fig. S25†), while 12, 15 and 19 all
yielded positive eﬀects. The results support our earlier conclu-
sion that the toxicity of these compounds is not simply related
to anion transport ability, and that non-toxic anion transport is
a realistic possibility.
Discussion
This study identied three anionophores, 12, 15, and 19, with
promising biological activity, while conrming the potential of
previously-studied 11. The agents were selected from a total of
22 molecules capable of anion transport in synthetic vesicles.
Given the general similarity of the molecules tested, in that all
bind anions through arrays of H-bond donor groups, the results
show striking variations in biological activity. Eﬀectiveness in
cells is presumably dependent on two factors: (i) the intrinsic
ability of the agent to transport anions, and (ii) the ability of
compounds to migrate to the membranes so that they can exert
their eﬀects. These can be assessed independently in synthetic
vesicles through measurements of specic initial transport
rates [I], and deliverability D (see Table 1). To some extent the
performance in LUVs correlates with that in cells. Thus, most of
the less active compounds show either low [I] or low D in LUVs
(Table 1). This said, of the four most active compounds, two
perform relatively poorly in one or other of the LUV assays; 11
gives [I] ¼ 22 s1, which is towards the low end of the scale,
while 15 gives D¼ 0.41. The divergence between performance in
cells and behaviour in LUVs may be an important topic for
future study.
In terms of structure–activity relationships, the trans-decalin
scaﬀold continues to be successful, being present in 11, 12 and
15. Previous work19,20,29 has highlighted the eﬀectiveness of this
system for transport in both vesicles and cells, and also for
tunability towards drug-like properties (e.g. small molecular
weight, controlled lipophilicity). Comparison of results for the
six decalin anionophores studied provides insight into the
structural features which enhance biological activity. First, the
length of the alkyl side chain; where comparisons can be made
(e.g. 12 vs. 13 and 15 vs. 16), the ethyl esters are far more active
than the corresponding octyl esters. This runs counter to the
trend observed in vesicle experiments,19 and probably reects
the poor deliverability of the longer-chain esters. Indeed, we
have previously shown that 16 is far more eﬀective when pre-
sented to cells using a coiled-coil-based delivery system.42
Second, substitution of ureas by thioureas oen improves anion
transport in LUVs.16,20 A possible reason is that urea oxygens are
good H-bond acceptors, binding to water molecules and thus
are less mobile within membranes.20 Accordingly, we nd here
that 12, a bis-thiourea decalin, possessed better biological
activity than 11, a bis-urea decalin. Third, uorination improves
anion transport by anionophores (e.g. 12 vs. 15, 18 vs. 19 and 21
vs. 22), probably by enhancing both lipophilicity and anion
aﬃnity.20,43
While the trans-decalins feature strongly among the most
active agents, other scaﬀolds can also be eﬀective. Anionophore
19, one of the four most promising agents, belongs to the tren-
based family,16,25 while anthracenes 20 and 22 24 are just slightlyThis journal is © The Royal Society of Chemistry 2019less eﬀective. Again, it seems that uorination enhances
transport activity; both 19 and 22 contain multiple tri-
uoromethyl substituents. None of the squaramides 1–3,22
hexa-substituted benzenes 4–7,23 or cyclohexane 8 21 proved
usefully active, probably due to poor deliverability. The squar-
amides tend to be insoluble, while compounds 4–8 are all highly
lipophilic. It seems likely that, in many cases, high lipophilicity
causes agents to precipitate in a form which hinders access to
cell membranes. This would also account for the failure of octyl-
substituted decalins 13 and 16, as discussed above.
Throughout this study, deliverability emerges as a key factor
which can limit the biological activity of anionophores. To
investigate anionophore delivery to cells, we varied the period
cells were incubated with anionophores 11, 12 and 19 prior to
assaying anion transport. For 12 and 19 prolonged incubation
periods enhanced noticeably anion transport, but for 11 there
was little improvement. It thus seems that 12 takes longer to
reach cell membranes, consistent with its relatively low deliv-
erability in vesicles. Like 11 (ref. 29; present results), 12
demonstrated noticeable persistence, mediating anion trans-
port for up to 2 h aer anionophore delivery to FRT cells,
despite the short incubation period and continuous perfusion
of cells with physiological salt solutions. Although it is known
that decalin anionophores do not leach from LUVs,19 the fate of
anionophores delivered to cells remains to be determined.
Cytotoxicity studies of anionophores have produced con-
icting results. Calixpyrroles and certain squaramides transport
anions in LUVs, but treatment of cells with these agents leads to
apoptotic cell death.44–46 By contrast, the decalin 11 has potent
biological activity yet is almost without toxic eﬀects on four
diﬀerent epithelial cell lines (ref. 29; present results). Interest-
ingly, the tren 19 was cytotoxic in some, but not all cancer cells
tested and was without toxic eﬀects on CF cells at concentra-
tions that mediated anion transport greater than that achieved
by CaCC activation (ref. 16; present results). Nevertheless,
higher concentrations of 19 as well as 12 and 15 exhibited some
cytotoxicity on CF cells and initiated apoptosis in FRT cells.
Taken together, these and other data44–46 argue that the cyto-
toxicity of anionophores is compound specic and anion
transport, by itself, does not trigger cell death. They also
support a variety of potential therapeutic applications for
anionophores, some as anticancer and antimicrobial
agents,45–47 but others as CF therapeutics.29,41,48
If anionophores are to be used as research tools, it is
important to establish their sensitivity to small molecules that
inhibit endogenous anion transport systems. We therefore
studied the eﬀects of CaCCinh-A01 (active against CaCC) and
CFTRinh-172 (active against CFTR),36,37 on transport by 11, 12,
15 and 19. 11 and 12 were unaﬀected by either CaCCinh-A01 or
CFTRinh-172, further demonstrating that their activity is inde-
pendent of endogenous pathways for anion transport in cells.
However, 19 was inhibited by both CaCCinh-A01 and CFTRinh-
172, possibly because the tren scaﬀold is more exible and
accessible to small molecule inhibitors.49 Surprisingly,
CFTRinh-172 increased anion transport by 15 by a small but
signicant degree. Further studies are required to understand
this eﬀect.Chem. Sci., 2019, 10, 9663–9672 | 9669
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View Article OnlineIn the present study, UTP activated little CaCC activity in CF
cells, probably due to low levels of expression of the CaCC
TMEM16A.34,35 By contrast, in the pro-inammatory conditions
of the CF lung, CaCC activity is enhanced strongly by increased
TMEM16A expression.35,50 Encouragingly, the present results
show that the activity of some anionophores, particularly the
tren 19, is additive to CaCC activation. These data argue that
some anionophores might be combined with small molecules
that directly target the CaCC TMEM16A in airway epithelia to
achieve sustained CaCC activity mimicking CFTR function.13
Future studies should explore this innovative approach to CFTR
bypass therapy.
Since 2012, drugs that target disease-causing variants in
CFTR have become available to CF patients.9–11 For individuals
with the F508del defect and those with some rare variants,
combination therapy with two or more CFTR correctors (drugs
that deliver variants to the cell membrane), together with
a potentiator (drugs that boost channel activity), may prove at
least partially eﬀective.51–53 However, not all individuals living
with CF are likely to benet from combination therapy with
CFTR modulators. These individuals will require CFTR variant-
independent therapies to restore anion transport to aﬀected
epithelial tissues. Moreover, patients who are helped by treat-
ment with CFTR correctors/potentiators may benet further
from complementary approaches, such as anion-transporting
small molecules, which restore bacterial killing to CF cells.54
Encouragingly, the present results and ref. 41 demonstrate that
the action of anionophores is additive to the clinically-licensed
CFTR modulators lumacaor and ivacaor, raising the possi-
bility that combination therapy with anionophores and CFTR
modulators might be used to treat CF patients. While ivacaor
and lumacaor are orally bioavailable drugs,39,40 we envisage
that anionophores would be delivered to the lungs of CF
patients by aerosolization as for inhaled antibiotics and gene
therapy vectors.7,55Conclusions
In conclusion, we show that anionophore evaluation using
uorescence emission from halide-sensitive YFP can be adapted
for use with a microplate reader to accelerate the identication
of anionophores with promising biological activity. We exploit
the method to test anionophores in several cell lines including
CF airway epithelial cells, a key target for CF therapeutics. We
demonstrate that our most promising anionophore 11 is eﬀec-
tive in YFP-modied CF airway epithelial cells, where it is
without cytotoxic eﬀects. Of note, the activity of some aniono-
phores is additive to CaCC activation, while the activity of 11
and three other biologically-active anionophores is additive to
rescue of the predominant CF-causing variant F508del-CFTR
using the clinically-licensed CFTR modulators lumacaor and
ivacaor. These data encourage us to believe that anionophores
might be developed to provide therapeutics for all individuals
with CF. They might be used alone or as part of a combination
therapy with either small molecule CaCC potentiators or CFTR
modulators.9670 | Chem. Sci., 2019, 10, 9663–9672Experimental
Cells and cell culture
FRT cells stably expressing YFP-H148Q/I152L28 were generous
gis of AS Verkman (University of California, San Francisco),
while CFBE41o cells34 stably expressing YFP were a generous
gi of LJV Galietta (Telethon Institute for Genetics and Medi-
cine). These cells were cultured as described in the ESI.†
Reagents
New anionophores (9, 10, 12 and 13) were synthesized as
described in the ESI;† all other anionophores and chemicals
were prepared and used as specied in the references (Table 1)
and ESI.†
Fluorescence plate reader assay
Anionophore-mediated anion transport was quantied by
measuring I-induced quenching of YFP uorescence at 37 C
using a microplate reader following the method of Galietta
et al.27 as described in the ESI.†
Statistics
Results are expressed as means  SEM of n observations. To
compare sets of data, we used Student's t-test. Diﬀerences were
considered statistically signicant when P < 0.05. All statistical
tests were performed using SigmaPlot 12 (Systat Soware Inc.,
San Jose, CA, USA).
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